M. Wainberg, G. Zaharatos, and B. Brenner, Development of Antiretroviral Drug Resistance, New England Journal of Medicine, vol.365, issue.7, pp.637-646, 2011.
DOI : 10.1056/NEJMra1004180

R. Ortiz, E. Dejesus, H. Khanlou, E. Voronin, and J. Van-lunzen, Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48, AIDS, vol.22, issue.12, pp.1389-1397, 2008.
DOI : 10.1097/QAD.0b013e32830285fb

J. Molina, J. Andrade-villanueva, J. Echevarria, P. Chetchotisakd, and J. Corral, Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study, The Lancet, vol.372, issue.9639, pp.646-655, 2008.
DOI : 10.1016/S0140-6736(08)61081-8

C. Delaugerre, P. Flandre, M. Chaix, J. Ghosn, and F. Raffi, Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy, Antimicrobial Agents and Chemotherapy, vol.53, issue.7, pp.2934-2939, 2009.
DOI : 10.1128/AAC.01643-08

M. Nijhuis, A. Wensing, W. Bierman, D. De-jong, and R. Kagan, Failure of Treatment with First???Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V, The Journal of Infectious Diseases, vol.200, issue.5, pp.698-709, 2009.
DOI : 10.1086/605329

Y. Mitsuya, T. Liu, S. Rhee, W. Fessel, and R. Shafer, Prevalence of Darunavir Resistance???Associated Mutations: Patterns of Occurrence and Association with Past Treatment, The Journal of Infectious Diseases, vol.196, issue.8, pp.1177-1179, 2007.
DOI : 10.1086/521624

C. De-mendoza, C. Garrido, A. Corral, N. Zahonero, and V. Soriano, Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance, AIDS, vol.22, issue.2, pp.311-313, 2008.
DOI : 10.1097/QAD.0b013e3282f4244f

C. Charpentier, F. Talla, E. Nguepi, A. Si-mohamed, and L. Bélec, Virological Failure and HIV Type 1 Drug Resistance Profiles Among Patients Followed-up in Private Sector, Douala, Cameroon, AIDS Research and Human Retroviruses, vol.27, issue.2, pp.221-230, 2011.
DOI : 10.1089/aid.2010.0103

S. Lambert-niclot, P. Flandre, A. Canestri, G. Peytavin, and C. Blanc, Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir, Antimicrobial Agents and Chemotherapy, vol.52, issue.2, pp.491-496, 2008.
DOI : 10.1128/AAC.00909-07

T. Young, N. Parkin, E. Stawiski, T. Pilot-matias, and R. Trinh, Prevalence, Mutation Patterns, and Effects on Protease Inhibitor Susceptibility of the L76V Mutation in HIV-1 Protease, Antimicrobial Agents and Chemotherapy, vol.54, issue.11, pp.4903-4906, 2010.
DOI : 10.1128/AAC.00906-10

F. Wiesmann, J. Vachta, R. Ehret, H. Walter, and R. Kaiser, The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?, AIDS Research and Therapy, vol.8, issue.1, p.7, 2011.
DOI : 10.1001/jama.2010.1004

A. Tartaglia, A. Saracino, L. Monno, C. Tinelli, and G. Angarano, Both a Protective and a Deleterious Role for the L76V Mutation, Antimicrobial Agents and Chemotherapy, vol.53, issue.4, pp.1724-1725, 2009.
DOI : 10.1128/AAC.01693-08

V. Johnson, V. Calvez, H. Günthard, R. Paredes, and D. Pillay, 2011 update of the drug resistance mutations in HIV-1, Top Antivir Med, vol.19, pp.156-164, 2011.

F. Ceccherini-silberstein, F. Erba, F. Gago, A. Bertoli, and F. Forbici, Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure, AIDS, vol.18, issue.12, pp.11-19, 2004.
DOI : 10.1097/01.aids.0000131394.76221.02

C. Alteri, V. Svicher, C. Gori, D. Arrigo, R. Ciccozzi et al., Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients na??ve to the antiretroviral drugs, BMC Infectious Diseases, vol.18, issue.suppl, p.111, 2009.
DOI : 10.1097/00002030-200401230-00012

C. Charpentier, S. Lambert-niclot, L. Larrouy, A. Storto, and R. Landman, Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations prevalence in HIV-1-infected patients experiencing virological failure between, Abstract of the 19 th Conference on Retroviruses and Opportunistic Infections, 2005.

K. Champenois, A. Baras, P. Choisy, F. Ajana, and H. Melliez, Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?, Journal of Medical Virology, vol.30, issue.10, pp.1677-1681, 2011.
DOI : 10.1093/ije/30.4.864

A. Deshpande, V. Jauvin, N. Magnin, P. Pinson, and M. Faure, Resistance Mutations in Subtype C HIV Type 1 Isolates from Indian Patients of Mumbai Receiving NRTIs Plus NNRTIs and Experiencing a Treatment Failure: Resistance to AR, AIDS Research and Human Retroviruses, vol.23, issue.2, pp.335-340, 2007.
DOI : 10.1089/aid.2006.0183

B. Brenner, D. Turner, M. Oliveira, D. Moisi, and M. Detorio, A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, vol.17, issue.1, pp.1-5, 2003.
DOI : 10.1097/00002030-200301030-00001

A. Ma?¨gama?¨ga, I. Malet, C. Soulie, A. Derache, and V. Koita, Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes, Antivir Ther, vol.14, pp.123-129, 2009.

F. Mammano, C. Petit, and F. Clavel, Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients, J Virol, vol.72, pp.7632-7637, 1998.

E. Dam, R. Quercia, B. Glass, D. Descamps, and O. Launay, Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss, PLoS Pathogens, vol.166, issue.3, p.1000345, 2009.
DOI : 10.1371/journal.ppat.1000345.s001

M. Nijhuis, N. Van-maarseveen, S. Lastere, P. Schipper, and E. Coakley, A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism, PLoS Medicine, vol.30, issue.1, p.36, 2007.
DOI : 10.1371/journal.pmed.0040036.st001

J. Ghosn, C. Delaugerre, P. Flandre, J. Galimand, and I. Cohen-codar, Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen, PLoS ONE, vol.10, issue.7, p.24798, 2011.
DOI : 10.1371/journal.pone.0024798.s001